Oct. 06. 2020
Osaka, Japan - October 5, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Dutasteride Capsules (the branded product: ZAGALLO®).
Dutasteride Capsules are prescribed for the treatment of male pattern alopecia.
The product approved by MHLW on October 5
| Product Name | Dutasteride Capsules ZA 0.5 mg [SAWAI] |
|---|---|
| Generic name | Dutasteride |
| Brand products | ZAGALLO® Capsules 0.5 mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.